It's another fail for AstraZeneca's I-O combo, but it may not mean what you think
admin 24th April 2018 Uncategorised 0AstraZeneca has come up short in another lung cancer trial of its immuno-oncology combo, this time in patients who’ve failed on two prior treatments. But investors shouldn’t use the outcome to predict the forthcoming results of a closely watched first-line study, analysts say.
More: It's another fail for AstraZeneca's I-O combo, but it may not mean what you think
Source: fierce